刘家曦

学术任务

日期	时间	会场	类型	Session/单元	题目
2023-12-24	08:00-08:15	702黄山(702黄山)	论文发言	论文交流	TACE Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors versus TACE Plus Tyrosine Kinase Inhibitors Alone as First-line Treatment for Patients with Hepatocellular Carcinoma: A Meta-Analysis and Trial Sequential Analysis